Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine in Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck
NCT00017498Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2001
- Primary completion
- Apr 2003
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in adenoid cystic carcinoma (ACC), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Objective Response Rate up to 36 weeks and Duration of Response. Started Feb 2001; status: completed.
02
Drugs
gemcitabine
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT00017498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00017498.